Literature DB >> 10326038

High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5.

M K Howard1, T Kershaw, B Gibb, N Storey, A R MacLean, B Y Zeng, B C Tel, P Jenner, S M Brown, C J Woolf, P N Anderson, R S Coffin, D S Latchman.   

Abstract

The safe and efficient use of herpes simplex virus (HSV)-based vectors to deliver genes of potentially therapeutic benefit to the central nervous system will require their effective disablement by the inactivation of viral genes required for lytic growth. Here we report that viruses lacking functional genes for ICP27 (which is required for growth in all cell types) and ICP34.5 (which is required for growth in nondividing cell types) can deliver a marker gene to both the rodent and primate CNS with high efficiency whilst producing relatively minimal damage and having no effect on sodium currents in dorsal root ganglion neurons. Such viruses paradoxically deliver genes at much higher efficiency than the less disabled single mutant lacking ICP34.5 alone and also, as expected, produce less damage in vivo. Moreover, unlike the single mutant lacking ICP27 the double mutant viruses cannot revert to wild-type by acquistion of complimenting gene sequences during growth of virus stocks in vitro on dividing cells expressing ICP27 since artificial expression of ICP34.5 in these cells is not required. Such ICP27-; ICP34.5- viruses thus offer a platform for the development of vectors which are sufficiently safe for ultimate use in human gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10326038     DOI: 10.1038/sj.gt.3300700

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Herpes simplex virus vectors for gene therapy in Parkinson's disease and other diseases of the nervous system.

Authors:  D S Latchman
Journal:  J R Soc Med       Date:  1999-11       Impact factor: 5.344

3.  RNA interference with special reference to combating viruses of crustacea.

Authors:  Kathy La Fauce; Leigh Owens
Journal:  Indian J Virol       Date:  2012-08-14

4.  Equine herpesvirus 1 gene 12 can substitute for vmw65 in the growth of herpes simplex virus (HSV) type 1, allowing the generation of optimized cell lines for the propagation of HSV vectors with multiple immediate-early gene defects.

Authors:  S K Thomas; C E Lilley; D S Latchman; R S Coffin
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Heat shock protein 70 or heat shock protein 27 overexpressed in human endothelial cells during posthypoxic reoxygenation can protect from delayed apoptosis.

Authors:  Alexander E Kabakov; Karina R Budagova; Anton L Bryantsev; David S Latchman
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

6.  Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.

Authors:  Eeva K Broberg; Jutta Peltoniemi; Michaela Nygårdas; Tero Vahlberg; Matias Röyttä; Veijo Hukkanen
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 7.  Medical relevance of UK-funded non-human primate research published from January 1997 to July 2012.

Authors:  Edward Moore
Journal:  J R Soc Med       Date:  2014-04-16       Impact factor: 5.344

Review 8.  Animal models for target diseases in gene therapy--using DNA and siRNA delivery strategies.

Authors:  Ian S Blagbrough; Chiara Zara
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.